Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Careful Observation of Ovarian Cysts Safe Alternative to Surgery
February 9th 2019

Careful Observation of Ovarian Cysts Safe Alternative to Surgery

Samantha DiGrande
Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.
This Week in Managed Care: February 8, 2019
February 8th 2019

This Week in Managed Care: February 8, 2019

This week, the top managed care news included President Trump's State of the Union address highlighting healthcare; HHS Secretary Alex Azar taking on drug rebates; and physicians asking Congress to fully implement the HITECH Act.
Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union
February 6th 2019

Trump Highlights New Initiatives for Childhood Cancer, HIV in State of the Union

Laura Joszt, MA
During his second State of the Union address, President Trump highlighted past bipartisan accomplishments, such as legislation to confront the opioid crisis, but also outlined future priorities, such as addressing the cost of healthcare and prescription drugs.
What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging
February 6th 2019

What We're Reading: Obesity and Cancer; Second Patient Treated Under Right-to-Try; Brain Aging

AJMC Staff
Cancers related to obesity are on the rise, especially among millennials; a right-to-try advocate is receiving treatment for his amyotrophic lateral sclerosis under the new law; and women's brains age more slowly than men's.
VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans
February 5th 2019

VA Contract Makes Foundation Medicine Oncology Tests Available to Veterans

Laura Joszt, MA
Foundation Medicine announced that it has won a nationwide contract from the Department of Veterans Affairs National Precision Oncology Program. The contract covers all of Foundation Medicine’s tests.
Chronic Pain the Top Reason US Patients Seek Medical Marijuana
February 5th 2019

Chronic Pain the Top Reason US Patients Seek Medical Marijuana

Allison Inserro
Chronic pain accounted for 62.2% of all patient-reported qualifying conditions under which US patients sought medical marijuana, according to a new paper in Health Affairs.
Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News
February 3rd 2019

Podcast: This Week in Managed Care—Congressional Drug Price Hearings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Predicting AML Outcomes by Monitoring Minimal Residual Disease
February 2nd 2019

Predicting AML Outcomes by Monitoring Minimal Residual Disease

Laura Joszt, MA
Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).
Review Identifies Potential Predictive Biomarkers in Colorectal Cancer
February 2nd 2019

Review Identifies Potential Predictive Biomarkers in Colorectal Cancer

David Bai, PharmD
A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).
This Week in Managed Care: February 1, 2019
February 1st 2019

This Week in Managed Care: February 1, 2019

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.
AJMC® in the Press, February 1, 2019
February 1st 2019

AJMC® in the Press, February 1, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year
January 31st 2019

ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year

Jaime Rosenberg
Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.
Discussing the Continuing Decline in Overall Cancer Mortality in the United States
January 30th 2019

Discussing the Continuing Decline in Overall Cancer Mortality in the United States

In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.
Site Logo
January 30th 2019

Mantle Cell Lymphoma (MCL): Treatment Landscape and Access to Care

https://www.pharmacytimes.org/on-demand/mantle-cell-lymphoma-mcl-treatment-landscape-and-access-to-care
Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say
January 29th 2019

Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say

Laura Joszt, MA
The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL
January 29th 2019

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

Jaime Rosenberg
The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).
Site Logo
January 23rd 2019

Managed Care Considerations in Meeting the Complex Needs of Patients with Pancreatic Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer
Treatment Advances Make Supportive Care More Important in Multiple Myeloma
January 22nd 2019

Treatment Advances Make Supportive Care More Important in Multiple Myeloma

Laura Joszt, MA
As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.
Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News
January 20th 2019

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance
January 20th 2019

Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance

As the first clinically integrated oncology network, the Quality Cancer Care Alliance (QCCA) brings together the best practices and shares knowledge on value-based care, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy
January 19th 2019

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

Jaime Rosenberg
Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.
Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19th 2019

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Laura Joszt, MA
Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.
Site Logo
January 19th 2019

AJMCtv® Interviews, January 2019

Samantha DiGrande Jaime Rosenberg
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Site Logo
January 19th 2019

Policy

Updates from the annual ASH meeting, December 2018.
This Week in Managed Care: January 18, 2019
January 18th 2019

This Week in Managed Care: January 18, 2019

This week, the top managed care news included a new investigation into drug prices; FDA Commissioner Scott Gottlieb, MD, provided updates on how the government shutdown is impacting FDA work; research found comorbidities impede clinical trial participation for patients with cancer.
Site Logo
January 18th 2019

Quality of Life

Updates from the annual ASH meeting, December 2018.
USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer
January 18th 2019

USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer

Samantha DiGrande
Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.
Site Logo
January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.
Site Logo
January 18th 2019

Cost of Care

Updates from the annual ASH meeting, December 2018.
Site Logo
January 17th 2019

Clinical: Lymphoma

Updates from the annual ASH meeting, December 2018.
<1
...
313233343536373839
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo